Translating Biomarker & Quality of Life Evaluation into Precision Medicine Approaches in HFpEF

Time: 1:45 pm
day: Day Two


  • Describe risk factors and disease endotypes in evaluation for HFpEF clinical trials
  • Define the state of proteomic/genomic, digital and cardiac imaging in precision medicine evaluation of HFpEF symptoms and disease progression
  • Discuss the evolving landscape of HFpEF clinical trials and opportunities
    for precision medicine